Share Offering Size Increased to 6.0M Shares
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 19 2026
0mins
Should l Buy GRDN?
The deal size was increased to 6.0M shares from 5.0M and priced inside the $30.60-$31.60 target range. BofA, Jefferies and Raymond James are acting as joint book running managers for the offering.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GRDN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GRDN
Wall Street analysts forecast GRDN stock price to fall
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 37.660
Low
34.00
Averages
34.50
High
35.00
Current: 37.660
Low
34.00
Averages
34.50
High
35.00
About GRDN
Guardian Pharmacy Services, Inc. is a long-term care pharmacy services company. Through its locally based business model, it partners with long-term care facilities (LTCF0073) to deliver medications, and a comprehensive suite of technology-enabled services designed to enhance care and improve adherence to drug regimens, helping to reduce the cost of care and improve clinical outcomes. Through its locally based pharmacies, the Company utilizes a complex, technology-enabled platform to manage the dispensing and administration of prescriptions to residents of LTCFs over the full prescription lifecycle in order to manage medication risk. Its Guardian Compass platform offers insights to enhance efficiency for its pharmacies, including proprietary real-time operational dashboards and metrics. Its suite of GuardianShield products offers customer and clinical services that benefit both the residents it serves and their caregivers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Five Stocks Added to Zacks Rank #1 (Strong Buy) List
- National Energy Services: National Energy Services Reunited Corp. (NESR) has seen a 6% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days, indicating growing market confidence in its profitability and potential stock price appreciation.
- Blue Bird Corporation: Blue Bird Corporation (BLBD) experienced an 8.3% rise in the Zacks Consensus Estimate for its current year earnings during the same period, reflecting strong demand in the school bus manufacturing sector, which is expected to enhance its market share.
- Permian Resources: Permian Resources Corporation (PR) saw a significant 53.1% increase in the Zacks Consensus Estimate for its current year earnings over the past 60 days, showcasing robust performance in the oil and gas industry that may attract more investor interest.
- Lifetime Brands: Lifetime Brands, Inc. (LCUT) recorded a 35.6% rise in the Zacks Consensus Estimate for its current year earnings in the same timeframe, indicating strong market demand for its kitchenware products, which is likely to drive company growth.
See More
Guardian Pharmacy Services Raises $186M in Upsized Public Offering
- Fundraising Success: Guardian Pharmacy Services raised approximately $186 million by selling 6 million Class A shares at $31 each, reflecting strong market demand for its stock.
- Share Structure: Of the total shares issued, about 4.98 million were sold by existing holders, while approximately 1.02 million were issued through a non-dilutive secondary offering, ensuring stability in the company's equity structure.
- Underwriter Option: The underwriters have a 30-day option to purchase up to 900,000 additional shares, which enhances liquidity and investor confidence in the stock.
- Repurchase Plan: Guardian plans to use all net proceeds from the offering to repurchase 1.02 million Class A shares, expected to close by March 24, 2026, thereby maintaining the existing shareholder equity without dilution.
See More
Guardian Pharmacy Services Proposes Public Offering of 5 Million Shares
- Public Offering Announcement: Guardian Pharmacy Services, Inc. has announced a proposed public offering of 5 million shares of Class A common stock, with 3.98 million shares from selling stockholders and 1.02 million newly issued shares, indicating the company's active engagement in capital markets.
- Non-Dilutive Transaction: The offering is considered non-dilutive as Guardian intends to use all net proceeds to repurchase an equal number of Class A shares, ensuring existing shareholders' interests are preserved and maintaining a stable capital structure.
- Underwriter Lineup: BofA Securities, Jefferies, and Raymond James are acting as joint bookrunners, while Stephens Inc. and Oppenheimer & Co. serve as co-managers, reflecting strong market confidence and support for the transaction.
- Regulatory Compliance: The registration statement for this offering became effective on November 3, 2025, complying with U.S. securities laws, ensuring the legality and transparency of the offering process.
See More
Guardian Pharmacy Services Reports Strong Q4 2025 Earnings
- Significant Revenue Growth: In Q4 2025, Guardian Pharmacy Services reported revenue of $397.6 million, a 17% year-over-year increase, with organic growth reaching 12%, demonstrating the company's strong performance in acquiring new residents and increasing script volume, thereby solidifying its market position.
- Adjusted EBITDA Surge: The company achieved a 53% year-over-year increase in adjusted EBITDA to $39.5 million, with margins expanding to 9.9%, reflecting successful operational efficiency and cost control, which enhances the sustainability of future profitability.
- Strong Cash Flow: As of Q4 2025, the company's cash balance rose to $66 million, up from $36 million in Q3, indicating robust cash generation capabilities that support future investments and acquisitions.
- Optimistic 2026 Outlook: The company raised its 2026 adjusted EBITDA guidance to $120 million to $124 million, reflecting confidence in ongoing growth drivers, while maintaining revenue expectations between $1.4 billion and $1.42 billion, showcasing adaptability to new pricing policies.
See More
Guardian Pharmacy (GRDN) Earnings Transcript
See More
Guardian Pharmacy Q4 Earnings Exceed Expectations
- Strong Earnings Report: Guardian Pharmacy Services reported a Q4 GAAP EPS of $0.37, beating expectations by $0.15, which demonstrates robust profitability growth and boosts investor confidence.
- Revenue Growth: The company achieved Q4 revenue of $397.6 million, exceeding market expectations by $7.56 million, reflecting its competitive position and sustained customer demand in the market.
- 2026 Outlook: The company raised its adjusted EBITDA guidance for FY 2026 to between $120 million and $124 million, up from the previous range of $115 million to $118 million, indicating management's optimistic outlook for future performance.
- Stable Revenue Expectations: The revenue forecast for FY 2026 remains between $1.40 billion and $1.42 billion, showcasing the company's confidence in revenue stability, which is expected to continue attracting investor interest.
See More
Five Stocks Added to Zacks Rank #1 (Strong Buy) List
- National Energy Services: National Energy Services Reunited Corp. (NESR) has seen a 6% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days, indicating growing market confidence in its profitability and potential stock price appreciation.
- Blue Bird Corporation: Blue Bird Corporation (BLBD) experienced an 8.3% rise in the Zacks Consensus Estimate for its current year earnings during the same period, reflecting strong demand in the school bus manufacturing sector, which is expected to enhance its market share.
- Permian Resources: Permian Resources Corporation (PR) saw a significant 53.1% increase in the Zacks Consensus Estimate for its current year earnings over the past 60 days, showcasing robust performance in the oil and gas industry that may attract more investor interest.
- Lifetime Brands: Lifetime Brands, Inc. (LCUT) recorded a 35.6% rise in the Zacks Consensus Estimate for its current year earnings in the same timeframe, indicating strong market demand for its kitchenware products, which is likely to drive company growth.
See More
Guardian Pharmacy Services Raises $186M in Upsized Public Offering
- Fundraising Success: Guardian Pharmacy Services raised approximately $186 million by selling 6 million Class A shares at $31 each, reflecting strong market demand for its stock.
- Share Structure: Of the total shares issued, about 4.98 million were sold by existing holders, while approximately 1.02 million were issued through a non-dilutive secondary offering, ensuring stability in the company's equity structure.
- Underwriter Option: The underwriters have a 30-day option to purchase up to 900,000 additional shares, which enhances liquidity and investor confidence in the stock.
- Repurchase Plan: Guardian plans to use all net proceeds from the offering to repurchase 1.02 million Class A shares, expected to close by March 24, 2026, thereby maintaining the existing shareholder equity without dilution.
See More
Guardian Pharmacy Services Proposes Public Offering of 5 Million Shares
- Public Offering Announcement: Guardian Pharmacy Services, Inc. has announced a proposed public offering of 5 million shares of Class A common stock, with 3.98 million shares from selling stockholders and 1.02 million newly issued shares, indicating the company's active engagement in capital markets.
- Non-Dilutive Transaction: The offering is considered non-dilutive as Guardian intends to use all net proceeds to repurchase an equal number of Class A shares, ensuring existing shareholders' interests are preserved and maintaining a stable capital structure.
- Underwriter Lineup: BofA Securities, Jefferies, and Raymond James are acting as joint bookrunners, while Stephens Inc. and Oppenheimer & Co. serve as co-managers, reflecting strong market confidence and support for the transaction.
- Regulatory Compliance: The registration statement for this offering became effective on November 3, 2025, complying with U.S. securities laws, ensuring the legality and transparency of the offering process.
See More
Guardian Pharmacy Services Reports Strong Q4 2025 Earnings
- Significant Revenue Growth: In Q4 2025, Guardian Pharmacy Services reported revenue of $397.6 million, a 17% year-over-year increase, with organic growth reaching 12%, demonstrating the company's strong performance in acquiring new residents and increasing script volume, thereby solidifying its market position.
- Adjusted EBITDA Surge: The company achieved a 53% year-over-year increase in adjusted EBITDA to $39.5 million, with margins expanding to 9.9%, reflecting successful operational efficiency and cost control, which enhances the sustainability of future profitability.
- Strong Cash Flow: As of Q4 2025, the company's cash balance rose to $66 million, up from $36 million in Q3, indicating robust cash generation capabilities that support future investments and acquisitions.
- Optimistic 2026 Outlook: The company raised its 2026 adjusted EBITDA guidance to $120 million to $124 million, reflecting confidence in ongoing growth drivers, while maintaining revenue expectations between $1.4 billion and $1.42 billion, showcasing adaptability to new pricing policies.
See More
Guardian Pharmacy (GRDN) Earnings Transcript
See More
Guardian Pharmacy Q4 Earnings Exceed Expectations
- Strong Earnings Report: Guardian Pharmacy Services reported a Q4 GAAP EPS of $0.37, beating expectations by $0.15, which demonstrates robust profitability growth and boosts investor confidence.
- Revenue Growth: The company achieved Q4 revenue of $397.6 million, exceeding market expectations by $7.56 million, reflecting its competitive position and sustained customer demand in the market.
- 2026 Outlook: The company raised its adjusted EBITDA guidance for FY 2026 to between $120 million and $124 million, up from the previous range of $115 million to $118 million, indicating management's optimistic outlook for future performance.
- Stable Revenue Expectations: The revenue forecast for FY 2026 remains between $1.40 billion and $1.42 billion, showcasing the company's confidence in revenue stability, which is expected to continue attracting investor interest.
See More
